Related references
Note: Only part of the references are listed.Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
Samantha Ho et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
Buonomo Antonio Riccardo et al.
JOURNAL OF NEUROLOGY (2022)
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
Marco Iannetta et al.
FRONTIERS IN IMMUNOLOGY (2022)
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
Carla Prezioso et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Monica Margoni et al.
JOURNAL OF NEUROLOGY (2022)
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann et al.
NATURE REVIEWS NEUROLOGY (2022)
Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study
Martin S. Weber et al.
FRONTIERS IN NEUROLOGY (2022)
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
Federica Dominelli et al.
FRONTIERS IN IMMUNOLOGY (2022)
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu et al.
FRONTIERS IN IMMUNOLOGY (2022)
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement
Lucia Moiola et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Bariatric surgery-induced weight loss reduces B cell activating cytokines and IgG immunoglobulins related to autoimmunity
Ricardo X. Cuellar-Tamez et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2021)
Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production
Zhicui Liu et al.
CELLULAR IMMUNOLOGY (2021)
Diagnosis and Treatment of Multiple Sclerosis A Review
Marisa P. McGinley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis
Zhuoyi Liu et al.
AUTOIMMUNITY REVIEWS (2021)
JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis
Maria Rosa Ciardi et al.
VIROLOGY JOURNAL (2020)
B Cell Activation and Response Regulation During Viral Infections
Jonathan H. Lam et al.
VIRAL IMMUNOLOGY (2020)
Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Carla Prezioso et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity
Rebecca A. Elsner et al.
IMMUNITY (2020)
HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab
M. I. R. Dudek et al.
JOURNAL OF NEUROLOGY (2019)
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Frederik Barkhof et al.
NEUROLOGY (2019)
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
Jodi L. Karnell et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
Treatment of multiple sclerosis - success from bench to bedside
Mar Tintore et al.
NATURE REVIEWS NEUROLOGY (2019)
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
Maria R. Ciardi et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells
Joana Machado-Santos et al.
BRAIN (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Reassessing B cell contributions in multiple sclerosis
Rui Li et al.
NATURE IMMUNOLOGY (2018)
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis
Antonio Scalfari et al.
NEUROLOGY (2018)
Multiple Sclerosis: Mechanisms and Immunotherapy
Clare Baecher-Allan et al.
NEURON (2018)
Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management
David J. Epstein et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
Thomas G. Forsthuber et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
Eileen Samy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
B cells from patients with multiple sclerosis. induce cell death via apoptosis in neurons in vitro
Robert P. Lisak et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Soluble CD40 ligand derived from serum is not correlated with early MS
Hamid Zahednasab et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Suzanne A. B. M. Aarts et al.
FRONTIERS IN IMMUNOLOGY (2017)
Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
Elena Grebenciucova et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
The Role of BAFF System Molecules in Host Response to Pathogens
Jiro Sakai et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
B cell-directed therapies in multiple sclerosis
Christiane Gasperi et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2016)
B Cells and Autoantibodies in Multiple Sclerosis
Anne-Katrin Proebstel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis
Don H. Mahad et al.
LANCET NEUROLOGY (2015)
B Cell Activating Factor (BAFF) and a Proliferation Inducing Ligand (APRIL) Mediate CD40-Independent Help by Memory CD4 T Cells
V. Gorbacheva et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome
Karin Kannel et al.
PLOS ONE (2015)
The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF)
Adriana Bornacelly et al.
BMC IMMUNOLOGY (2014)
B cells in MS and NMO: pathogenesis and therapy
Markus Krumbholz et al.
SEMINARS IN IMMUNOPATHOLOGY (2014)
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
Tamara Castillo-Trivino et al.
PLOS ONE (2013)
Cortical lesion load associates with progression of disability in multiple sclerosis
Massimiliano Calabrese et al.
BRAIN (2012)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
B cells in multiple sclerosis: connecting the dots
H-Christian von Buedingen et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
A REASSESSMENT OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS
John F. Kurtzke
ACTA NEUROLOGICA SCANDINAVICA (2010)
Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population
Adi Vaknin-Dembinsky et al.
MULTIPLE SCLEROSIS (2010)
Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged
Yu Cheng Tang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection
G. Tarantino et al.
JOURNAL OF VIRAL HEPATITIS (2009)
B-cell-directed therapies for autoimmune disease
Thomas Doerner et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
Frederic Lavie et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome
Raphaele Seror et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: Association with autoimmunity
E. Toubi et al.
JOURNAL OF AUTOIMMUNITY (2006)
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse
G Cambridge et al.
ARTHRITIS AND RHEUMATISM (2006)
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
Therese Vallerskog et al.
ARTHRITIS RESEARCH & THERAPY (2006)
BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway
A Craxton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The BAFF/APRIL system: life beyond B lymphocytes
LG Ng et al.
MOLECULAR IMMUNOLOGY (2005)
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma
M Krumbholz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Share Paper
